Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed August 24, 2026
The circular logic problem hiding in your liver panel Every reference range on your blood test was built the same way: a lab draws blood from a large group of "apparently healthy" people, plots the results, and calls the middle 95 percent normal. That method works fine when the disease you are screening for is rare. It fails badly when the disease is common, silent, and undiagnosed in the very…
This dispatch covers Your Liver Enzyme Is 'Normal' Because the Range Was Built on People With Fatty Livers in the research research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 8 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Every reference range on your blood test was built the same way: a lab draws blood from a large group of "apparently healthy" people, plots the results, and calls the middle 95 percent normal.
That method works fine when the disease you are screening for is rare. It fails badly when the disease is common, silent, and undiagnosed in the very population used to build the range.
That is exactly what happened to ALT, the most commonly ordered liver enzyme in the world.
Roughly one in three adults now has metabolic dysfunction-associated steatotic liver disease, the condition formerly called non-alcoholic fatty liver disease. A 2023 meta-analysis in Hepatology covering more than 2.4 million individuals put global prevalence at about 38 percent, up from around 25 percent two decades earlier. Most of those people have no symptoms, no diagnosis, and no idea. Many of them donated blood, enrolled in reference studies, and got counted as "healthy."
The result: the ALT range printed on your lab report was partly calibrated on people whose livers were already accumulating fat. The bar for "normal" was set by a population that was quietly getting sick.
Depending on the lab, the upper limit of normal for ALT is typically printed somewhere between 40 and 55 U/L for men and slightly lower for women.
The research says those numbers are too generous.
The landmark study here is Prati and colleagues, published in Annals of Internal Medicine in 2002. The investigators took a different approach to defining normal: instead of accepting the whole donor pool, they restricted the reference population to blood donors at the lowest risk of liver disease, screening out hepatitis C, hepatitis B, medication exposure, and, critically, metabolic risk factors like elevated BMI, abnormal lipids, and abnormal glucose.
When the population was actually healthy, the upper limit of normal dropped to roughly 30 U/L for men and 19 U/L for women.
That is not a fringe finding. The American College of Gastroenterology's 2017 guideline on abnormal liver chemistries adopted essentially the same position, recommending a true upper limit of 29 to 33 U/L for men and 19 to 25 U/L for women, and stating plainly that many laboratory ranges are set too high.
Sit with the gap for a moment. A 45-year-old man with an ALT of 42 is told he is normal by a lab using a cutoff of 55. Against the evidence-based threshold, he is roughly 40 percent above the upper limit, and elevated ALT in that range is associated with insulin resistance, hepatic fat accumulation, and increased liver-related and cardiovascular mortality in long-term cohort studies.
He will never hear about any of that, because the flag on the report stayed green.
In 2023, the major international liver societies retired the term NAFLD and replaced it with MASLD: metabolic dysfunction-associated steatotic liver disease. The rename matters beyond vocabulary. The new definition requires the presence of at least one cardiometabolic risk factor, which is an explicit acknowledgment of what the research had shown for years: fatty liver is not primarily a liver problem. It is the hepatic expression of metabolic dysfunction.
The liver is where excess energy goes when your adipose tissue runs out of safe storage capacity and insulin signaling starts to fail. Fat accumulating in hepatocytes is a downstream marker of the same process that drives elevated fasting insulin, rising triglycerides, falling HDL, and expanding waist circumference. In practice, MASLD, insulin resistance, and visceral adiposity travel together so consistently that finding one should trigger a search for the other two.
This is why an ALT creeping from 22 to 34 over three years is information, even though every single result was "normal." Trajectory within the range often tells you more than any single crossing of it.
Here is the part that surprises people: ALT is not just miscalibrated at the top. It also misses disease entirely.
A 2003 study by Mofrad and colleagues in Hepatology examined patients with biopsy-proven fatty liver disease whose ALT was persistently normal. The full histologic spectrum was present, including steatohepatitis and advanced fibrosis. Normal ALT did not mean a normal liver. Later cohort work has repeatedly confirmed it: a substantial fraction of people with MASLD, including some with significant fibrosis, sit inside the standard ALT range their whole lives.
So the marker fails both ways:
This is not a reason to ignore ALT. It is a reason to stop treating it as a binary pass/fail and start reading it in context.
A more useful framework, drawn from the hepatology literature rather than the lab report footer:
1. Use evidence-based cutoffs, not the printed range. For screening purposes, treat sustained ALT above roughly 30 U/L in men and 19 to 25 U/L in women as a signal worth explaining, especially alongside any metabolic risk factor. Lower is generally better within reason; large Korean and Finnish cohort studies found the lowest all-cause and cardiovascular mortality at ALT levels well inside the conventional range.
2. Look at the AST:ALT relationship. In early metabolic liver disease, ALT typically runs higher than AST. A ratio that inverts, with AST climbing above ALT in the absence of alcohol, can accompany advancing fibrosis and deserves attention.
3. Calculate FIB-4 before ordering anything exotic. The FIB-4 index combines four values you already have: age, AST, ALT, and platelet count. It costs nothing and is endorsed in the AASLD and ADA pathways as the first-line triage tool for fibrosis risk. Below about 1.3, advanced fibrosis is unlikely. Above 2.67, the probability rises enough to justify imaging-based elastography and specialist referral. The zone between is where repeat testing and secondary tests earn their keep.
4. Interpret ALT alongside the metabolic panel, not in isolation. Fasting insulin, triglyceride:HDL ratio, HbA1c, waist-to-height ratio, and GGT form the cluster that gives a mid-range ALT its meaning. An ALT of 33 with a fasting insulin of 4 and lean body composition reads very differently from the same number sitting next to an insulin of 15 and a triglyceride:HDL ratio of 3.5.
5. Rule out the non-metabolic causes. Medications (statins, acetaminophen, some antibiotics and antifungals), alcohol, viral hepatitis, thyroid dysfunction, celiac disease, and intense resistance training in the days before the draw can all move aminotransferases. One elevated result is a prompt to repeat, not a diagnosis.
Two reasons.
First, scale. MASLD is on track to become the leading indication for liver transplant in the United States. A condition affecting more than a third of adults, screened primarily by a single enzyme whose reference range was contaminated by the disease itself, is a public health blind spot of unusual size.
Second, reversibility. Unlike many findings on a blood panel, hepatic fat responds quickly and dramatically to intervention. Weight loss of 7 to 10 percent of body weight has been shown to resolve steatohepatitis in the majority of patients who achieve it. Reductions in refined carbohydrate intake, improvements in insulin sensitivity, resistance training, and adequate protein all move liver fat measurably within months. In the GLP-1 era, several agents have shown meaningful resolution of steatohepatitis in trials, with resmetirom becoming the first FDA-approved therapy specifically for MASH fibrosis in 2024. The window between "fat accumulation" and "fibrosis" is wide, and it is the window in which nearly everything works.
An honest reading of one cheap enzyme, three years earlier, is often the difference between a lifestyle correction and a hepatology referral.
Your ALT result comes with a reference range built, in part, on people who already had the disease the test is supposed to catch. The evidence-based upper limit is roughly 30 U/L for men and 19 to 25 U/L for women, far below what most lab reports print. A normal flag excludes very little, an upward trend within the range is a real signal, and a two-minute FIB-4 calculation from values you already have does more triage work than the reference range ever will.
The pattern by now should be familiar to regular readers of this series: the question is never just "is the number in range." It is "who was the range built on, and what does this number mean for someone trying to stay well rather than merely avoid a diagnosis."
This article is for educational purposes only and is not medical advice. Reference ranges, risk thresholds, and treatment decisions should be discussed with a licensed clinician who can evaluate your full history and lab work in context.
Sources: Prati D, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10. Kwo PY, et al. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. Younossi ZM, et al. The global epidemiology of NAFLD/MASLD: a systematic review and meta-analysis. Hepatology. 2023;77(4):1335-1347. Mofrad P, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-1292. Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.